Contents

1	Radioactivity, Radionuclides, an	d
	Radiopharmaceuticals, 1	

- 2 Instrumentation and Quality Control, 19
- 3 Central Nervous System, 60
- 4 Thyroid, Parathyroid, and Salivary Glands, 85
- 5 Cardiovascular System, 116
- 6 Respiratory System, 175
- 7 Gastrointestinal Tract, 213
- 8 Skeletal System, 243
- 9 Genitourinary System and Adrenal Glands, 287
- 10 Non-PET Neoplasm Imaging and Radionuclide Therapy, 315
- 11 Hybrid PET/CT Neoplasm Imaging, 328
- 12 Inflammation and Infection Imaging, 362
- 13 Authorized User and Radioisotope Safety Issues, 382

SELF-EVALUATION

Unknown Case Sets, 402

Answers to Unknown Case Sets, 465

APPENDICES

- A Characteristics of Radionuclides for Imaging and Therapy, 476
- B.1 Radioactivity Conversion Table for International System (SI) Units (Becquerels to Curies), 478
- B.2 Radioactivity Conversion Table for International System (SI) Units (Curies to Becquerels), 479
- C.1 Technetium-99m Decay and Generation Tables, 480
- C.2 Other Radionuclide Decay Tables, 482
- D Injection Techniques and Pediatric Dosages, 484
- E Sample Techniques for Nuclear Imaging, 488
- F Nonradioactive Pharmaceuticals in Nuclear Medicine, 512
- G Pregnancy and Breastfeeding, 513
- H.1 General Considerations for Hospitalized
 Patients Receiving Radionuclide Therapy, 516
- H.2 Special Considerations and Requirements for lodine-131 Therapy, 520
- Emergency Procedures for Spills of Radioactive Materials and Special Circumstances, 522